Catalyst Biosciences to Present at the Stifel Immunology and Inflammation Summit
Catalyst Biosciences, based in South San Francisco, announced that Dr. Grant Blouse will present at the Stifel Immunology and Inflammation Virtual Summit on October 1, 2020, at 9:00 AM ET. He will discuss the evolution of complement-targeted therapies. Interested participants can access the live presentation via a provided link, with an archived version available for 90 days post-event. Catalyst is focused on biopharmaceutical developments, particularly in rare hematologic disorders, with advanced clinical programs, including marzeptacog alfa and dalcinonacog alfa.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that Grant Blouse, Ph.D., senior vice president of translational research, will present at the Stifel Immunology and Inflammation Virtual Summit. Dr. Blouse will speak on a panel entitled: “The evolution of complement targeted therapies,” taking place on Thursday, October 1, 2020, at 9:00 AM Eastern Time.
To access a live webcast of the panel presentation, please click here.
An archived webcast of the presentation will be available for 90 days on the Events and Presentations section on the Company’s website.
About Catalyst Biosciences
Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet needs in rare hematologic and complement-mediated disorders. Our protease engineering platform includes two late-stage clinical programs in hemophilia; a research program on the engineering of subcutaneous (SQ) complement inhibitors; and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). The product candidates generated by our protease engineering platform have improved functionality and potency that allow for: SQ administration of recombinant coagulation factors and complement inhibitors; low-dose, high activity gene therapy constructs; and less frequently dosed intravitreal therapeutics. Our most advanced product candidate is marzeptacog alfa (activated) (MarzAA), a next-generation SQ FVIIa entering a Phase 3 registration study in late 2020. Our next late-stage product candidate is dalcinonacog alfa (DalcA), a next-generation SQ FIX, which has demonstrated efficacy and safety in a Phase 2b clinical trial in individuals with Hemophilia B. We have a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, that has demonstrated superiority compared with the Padua variant in preclinical models. Finally, we have a global license and collaboration agreement with Biogen for the development and commercialization of anti-complement Factor 3 (C3) pegylated CB 2782.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements about the potential benefits of products based on Catalyst’s engineered protease platform, plans to enroll the first patients in a Phase 3 registration study of MarzAA in late 2020, the potential for MarzAA and DalcA to effectively and therapeutically treat hemophilia subcutaneously, the superiority of CB 2679d-GT over other gene therapy, and the development of anti-complement Factor 3 (C3) pegylated CB 2782 by Biogen. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially, including, but not limited to, the risk that trials and studies may be delayed as a result of the COVID-19 pandemic and other factors, that trials may not have satisfactory outcomes, that additional human trials will not replicate the results from earlier trials, that potential adverse effects may arise from the testing or use of DalcA or MarzAA, including the generation of neutralizing antibodies, which has been observed in patients treated with DalcA, the risk that costs required to develop or manufacture the Company’s products will be higher than anticipated, including as a result of delays in development and manufacturing resulting from COVID-19 and other factors, the risk that Biogen will terminate Catalyst’s agreement, competition and other risks described in the “Risk Factors” section of the Company’s quarterly report filed with the Securities and Exchange Commission on August 6, 2020, and in other filings with the Securities and Exchange Commission. The Company does not assume any obligation to update any forward-looking statements, except as required by law.
Contact:
Ana Kapor
Catalyst Biosciences, Inc.
investors@catbio.com
FAQ
What is Catalyst Biosciences' focus area?
Who will present at the Stifel Immunology Summit?
When is Dr. Blouse's presentation at the virtual summit?
How can I access the presentation by Catalyst Biosciences?
What are the key product candidates of Catalyst Biosciences?
What upcoming studies are planned for marzeptacog alfa?
What challenges does Catalyst Biosciences face?
